CurrentCignaPolicy IP0729

Phexx

This policy governs prior authorization and coverage criteria for Phexx (lactic acid, citric acid, and potassium bitartrate vaginal gel) as an on‑demand contraceptive for females of reproductive potential under Cigna benefit plans.

Policy Summary

PayerCigna

PolicyPhexx (vaginal contraceptive gel)

Policy CodePolicy IP0729

Change TypeNew policy with material updates

Effective Date09/15/2025

Next Review Date

Key ActionObtain prior authorization and document that the patient has tried three other barrier methods before approving for a 6‑month period.

SourceLink

POLICY UPDATE CHANGES

Policy created as a new drug coverage policy for Phexx.

Updated policy statement to include wording 'or for the improvement of birth outcomes.'

Name change noted: Phexxi renamed to Phexx in May 2025.

6 monthsauthorization duration

3required prior methods

1 houradminister within

5 gdose

Not effective after intercourselimitation

Coverage Criteria for Phexx

Initial Authorization Criteria

Covered when ALL of the following are met

FDA indication

Prior methods: Patient has tried THREE other barrier methods of contraception (diaphragms, condoms, spermicides, or sponges)3 methods
If this criterion is met, approve for 6 months
Administration timing: Planned use is one 5‑gram prefilled applicator vaginally administered immediately before or up to one hour before each act of vaginal intercourse; if more than one act of vaginal intercourse occurs within one hour, an additional dose must be used<=1 hour
Phexx is not effective if administered after intercourse

Policy Summary

PayerCigna

PolicyPhexx (vaginal contraceptive gel)

Policy CodePolicy IP0729

Change TypeNew policy with material updates

Effective Date09/15/2025

Next Review Date

Key ActionObtain prior authorization and document that the patient has tried three other barrier methods before approving for a 6‑month period.

SourceLink

On This Page

Use of Phexx outside its FDA‑approved indication for prevention of pregnancy is expressly excluded. Specifically, Phexx is not covered when used as a personal lubricant; although some ingredients were previously marketed over‑the‑counter for lubrication, the product is indicated only for contraception. The policy also excludes use for treatment of acute bacterial vaginosis, since available acidic‑gel treatments have shown inferior effectiveness compared with standard therapies. Finally, Phexx is not covered for protection against HIV or other sexually transmitted infections, per product labeling.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization is required for benefit coverage of Phexx. All approvals are provided for the duration noted in the policy (when months are used, 1 month = 30 days).

Approval duration: 6 months when criteria are met

Step Therapy

Step Therapy / Prior Use Requirement

Patient must have tried THREE other barrier methods of contraception prior to approval (examples: diaphragms, condoms, spermicides, sponges). Approve for 6 months when this step-therapy/prior-use requirement is met.

Required prior methods: diaphragms; condoms; spermicides; sponges
Exception: If ACA/HRSA/PHS Act §2713 compliance applies and medically necessary criteria are not met, approval may be granted for prevention of pregnancy or improved birth outcomes if prescriber attests other barrier methods are not as medically appropriate

Documentation Required

Required Documentation and Duration

Documentation to support prior use of three barrier methods and any prescriber attestation for exceptions must be submitted with the authorization request. Receipt of sample product does not satisfy criteria requirements for coverage.

Document prior use: dates, medication/device names, and clinical rationale
If invoking ACA/HRSA/PHS exception: include prescriber statement explaining why other barrier methods are not as medically appropriate

Denial Risk

Denial Risk for Improper Coding or Insufficient Documentation

Claims submitted without covered diagnosis/procedure codes or with insufficient documentation (including lack of evidence of prior use or missing prescriber attestation when required) may be denied.

Denial risk if billing without covered diagnosis/procedure codes
Denial risk if documentation does not demonstrate trial of three barrier methods or applicable exception

Background

Phexx is an on‑demand vaginal gel indicated only for prevention of pregnancy in females of reproductive potential. Its mechanism involves lowering vaginal pH to reduce sperm motility. The recommended administration is one 5‑gram prefilled applicator inserted vaginally immediately before or up to one hour before intercourse; it is not effective if used after intercourse. Clinical data do not support use for bacterial vaginosis or sexually transmitted infection prevention.

Definitions

Phexx (vaginal gel) — definition and use

IndicationPrevention of pregnancy in females of reproductive potential as an on‑demand method of contraception.

Administration timingOne 5‑gram prefilled applicator vaginally administered immediately before or up to one hour before each act of vaginal intercourse; additional dose required if more than one act occurs within one hour.

Limitation of useNot effective for prevention of pregnancy when administered after intercourse.

Active components / mechanismContains lactic acid, citric acid, and potassium bitartrate; in vitro pH lowering and reduction in sperm motility contribute to activity.

Product naming/historyPreviously known under names such as Amphora and Acidform; name changed to Phexx in May 2025.